Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
Norazida Ab Rahman(Hospital Kuala Lumpur), Kalaiarasu M. Peariasamy(Ministry of Health), Nor Aliya Ayub(Hospital Kuala Lumpur), Sheamini Sivasampu(Ministry of Health), Siti Nurhafizah Saharudin, Rashidah Bahari, Teck Long King(Sarawak General Hospital), Emelyne Bani Anak Jam, Ming Tsuey Lim, Sing Chet Lee, Fei Yee Lee, Nor Nadziroh Ibrahim, Raj Kumar Sevalingam(Hospital Kuala Lumpur)
Cited by 41
Related Papers
Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis
|The Lancet Digital Health|2022|178
Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
|The Lancet Regional Health - Western Pacific|2020|132
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
|JAMA Internal Medicine|2022|105
Influence of Population Density for COVID-19 Spread in Malaysia: An Ecological Study
|International Journal of Environmental Research and Public Health|2021|85
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
|International Journal of Infectious Diseases|2022|79